150 related articles for article (PubMed ID: 38599221)
1. Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials.
Butler J; Shah SJ; Petrie MC; Borlaug BA; Abildstrøm SZ; Davies MJ; Hovingh GK; Kitzman DW; Møller DV; Verma S; Einfeldt MN; Lindegaard ML; Rasmussen S; Abhayaratna W; Ahmed FZ; Ben-Gal T; Chopra V; Ezekowitz JA; Fu M; Ito H; Lelonek M; Melenovský V; Merkely B; Núñez J; Perna E; Schou M; Senni M; Sharma K; van der Meer P; Von Lewinski D; Wolf D; Kosiborod MN;
Lancet; 2024 Apr; 403(10437):1635-1648. PubMed ID: 38599221
[TBL] [Abstract][Full Text] [Related]
2. Effects of Semaglutide on Symptoms, Function, and Quality of Life in Patients With Heart Failure With Preserved Ejection Fraction and Obesity: A Prespecified Analysis of the STEP-HFpEF Trial.
Kosiborod MN; Verma S; Borlaug BA; Butler J; Davies MJ; Jon Jensen T; Rasmussen S; Erlang Marstrand P; Petrie MC; Shah SJ; Ito H; Schou M; Melenovský V; Abhayaratna W; Kitzman DW;
Circulation; 2024 Jan; 149(3):204-216. PubMed ID: 37952180
[TBL] [Abstract][Full Text] [Related]
3. Semaglutide and NYHA Functional Class in Obesity-Related Heart Failure With Preserved Ejection Fraction: The STEP-HFpEF Program.
Schou M; Petrie MC; Borlaug BA; Butler J; Davies MJ; Kitzman DW; Shah SJ; Verma S; Patel S; Chinnakondepalli KM; Harring S; Abildstrøm SZ; Liisberg K; Kosiborod MN;
J Am Coll Cardiol; 2024 Jun; ():. PubMed ID: 38913004
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of Semaglutide by Sex in Obesity-Related Heart Failure With Preserved Ejection Fraction: STEP-HFpEF Trials.
Verma S; Butler J; Borlaug BA; Davies M; Kitzman DW; Shah SJ; Petrie MC; Barros E; Rönnbäck C; Vestergaard LS; Schou M; Ezekowitz JA; Sharma K; Patel S; Chinnakondepalli KM; Kosiborod MN;
J Am Coll Cardiol; 2024 Jun; ():. PubMed ID: 38913003
[TBL] [Abstract][Full Text] [Related]
5. Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes.
Kosiborod MN; Petrie MC; Borlaug BA; Butler J; Davies MJ; Hovingh GK; Kitzman DW; Møller DV; Treppendahl MB; Verma S; Jensen TJ; Liisberg K; Lindegaard ML; Abhayaratna W; Ahmed FZ; Ben-Gal T; Chopra V; Ezekowitz JA; Fu M; Ito H; Lelonek M; Melenovský V; Merkely B; Núñez J; Perna E; Schou M; Senni M; Sharma K; van der Meer P; Von Lewinski D; Wolf D; Shah SJ;
N Engl J Med; 2024 Apr; 390(15):1394-1407. PubMed ID: 38587233
[TBL] [Abstract][Full Text] [Related]
6. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.
Kosiborod MN; Abildstrøm SZ; Borlaug BA; Butler J; Rasmussen S; Davies M; Hovingh GK; Kitzman DW; Lindegaard ML; Møller DV; Shah SJ; Treppendahl MB; Verma S; Abhayaratna W; Ahmed FZ; Chopra V; Ezekowitz J; Fu M; Ito H; Lelonek M; Melenovsky V; Merkely B; Núñez J; Perna E; Schou M; Senni M; Sharma K; Van der Meer P; von Lewinski D; Wolf D; Petrie MC;
N Engl J Med; 2023 Sep; 389(12):1069-1084. PubMed ID: 37622681
[TBL] [Abstract][Full Text] [Related]
7. Design and Baseline Characteristics of STEP-HFpEF Program Evaluating Semaglutide in Patients With Obesity HFpEF Phenotype.
Kosiborod MN; Abildstrøm SZ; Borlaug BA; Butler J; Christensen L; Davies M; Hovingh KG; Kitzman DW; Lindegaard ML; Møller DV; Shah SJ; Treppendahl MB; Verma S; Petrie MC
JACC Heart Fail; 2023 Aug; 11(8 Pt 1):1000-1010. PubMed ID: 37294245
[TBL] [Abstract][Full Text] [Related]
8. Semaglutide and Diuretic Use in Obesity-Related Heart Failure with Preserved Ejection Fraction: A Pooled Analysis of the STEP-HFpEF and STEP-HFpEF-DM trials.
Shah SJ; Sharma K; Borlaug BA; Butler J; Davies M; Kitzman DW; Petrie MC; Verma S; Patel S; Chinnakondepalli KM; Einfeldt MN; Jensen TJ; Rasmussen S; Asleh R; Ben-Gal T; Kosiborod MN
Eur Heart J; 2024 May; ():. PubMed ID: 38739118
[TBL] [Abstract][Full Text] [Related]
9. Semaglutide and NT-proBNP in Obesity-Related HFpEF: Insights From the STEP-HFpEF Program.
Petrie MC; Borlaug BA; Butler J; Davies MJ; Kitzman DW; Shah SJ; Verma S; Jensen TJ; Einfeldt MN; Liisberg K; Perna E; Sharma K; Ezekowitz JA; Fu M; Melenovský V; Ito H; Lelonek M; Kosiborod MN;
J Am Coll Cardiol; 2024 Jul; 84(1):27-40. PubMed ID: 38819334
[TBL] [Abstract][Full Text] [Related]
10. Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial.
Borlaug BA; Kitzman DW; Davies MJ; Rasmussen S; Barros E; Butler J; Einfeldt MN; Hovingh GK; Møller DV; Petrie MC; Shah SJ; Verma S; Abhayaratna W; Ahmed FZ; Chopra V; Ezekowitz J; Fu M; Ito H; Lelonek M; Melenovsky V; Núñez J; Perna E; Schou M; Senni M; van der Meer P; Von Lewinski D; Wolf D; Kosiborod MN
Nat Med; 2023 Sep; 29(9):2358-2365. PubMed ID: 37635157
[TBL] [Abstract][Full Text] [Related]
11. Semaglutide in Patients With Obesity and Heart Failure Across Mildly Reduced or Preserved Ejection Fraction.
Butler J; Abildstrøm SZ; Borlaug BA; Davies MJ; Kitzman DW; Petrie MC; Shah SJ; Verma S; Abhayaratna WP; Chopra V; Ezekowitz JA; Fu M; Ito H; Lelonek M; Núñez J; Perna E; Schou M; Senni M; van der Meer P; von Lewinski D; Wolf D; Altschul RL; Rasmussen S; Kosiborod MN
J Am Coll Cardiol; 2023 Nov; 82(22):2087-2096. PubMed ID: 37993201
[TBL] [Abstract][Full Text] [Related]
12. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial.
Kadowaki T; Isendahl J; Khalid U; Lee SY; Nishida T; Ogawa W; Tobe K; Yamauchi T; Lim S;
Lancet Diabetes Endocrinol; 2022 Mar; 10(3):193-206. PubMed ID: 35131037
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial.
Sorli C; Harashima SI; Tsoukas GM; Unger J; Karsbøl JD; Hansen T; Bain SC
Lancet Diabetes Endocrinol; 2017 Apr; 5(4):251-260. PubMed ID: 28110911
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.
Ahrén B; Masmiquel L; Kumar H; Sargin M; Karsbøl JD; Jacobsen SH; Chow F
Lancet Diabetes Endocrinol; 2017 May; 5(5):341-354. PubMed ID: 28385659
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial.
Mosenzon O; Blicher TM; Rosenlund S; Eriksson JW; Heller S; Hels OH; Pratley R; Sathyapalan T; Desouza C;
Lancet Diabetes Endocrinol; 2019 Jul; 7(7):515-527. PubMed ID: 31189517
[TBL] [Abstract][Full Text] [Related]
16. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.
Davies M; Færch L; Jeppesen OK; Pakseresht A; Pedersen SD; Perreault L; Rosenstock J; Shimomura I; Viljoen A; Wadden TA; Lingvay I;
Lancet; 2021 Mar; 397(10278):971-984. PubMed ID: 33667417
[TBL] [Abstract][Full Text] [Related]
17. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial.
Pratley R; Amod A; Hoff ST; Kadowaki T; Lingvay I; Nauck M; Pedersen KB; Saugstrup T; Meier JJ;
Lancet; 2019 Jul; 394(10192):39-50. PubMed ID: 31186120
[TBL] [Abstract][Full Text] [Related]
18. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial.
Enebo LB; Berthelsen KK; Kankam M; Lund MT; Rubino DM; Satylganova A; Lau DCW
Lancet; 2021 May; 397(10286):1736-1748. PubMed ID: 33894838
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of semaglutide in patients with heart failure with preserved ejection fraction and obesity.
Rehman A; Saidullah S; Asad M; Gondal UR; Ashraf A; Khan MF; Akhtar W; Mehmoodi A; Malik J
Clin Cardiol; 2024 May; 47(5):e24283. PubMed ID: 38767042
[TBL] [Abstract][Full Text] [Related]
20. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial.
Zinman B; Bhosekar V; Busch R; Holst I; Ludvik B; Thielke D; Thrasher J; Woo V; Philis-Tsimikas A
Lancet Diabetes Endocrinol; 2019 May; 7(5):356-367. PubMed ID: 30833170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
